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Abstract 
Background: The introduction of more sensitive cardiac troponin assays has led to increased 
recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The 
Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin (hs-
cTn) testing and classification of patients with myocardial injury based on aetiology, but the 
clinical implications of implementing this guideline are not well understood. 
Methods: In a stepped-wedge cluster randomized controlled trial, we implemented a hs-cTn 
assay and the recommendations of the Universal Definition in 48,282 consecutive patients with 
suspected acute coronary syndrome. In a pre-specified secondary analysis, we compared the 
primary outcome of myocardial infarction or cardiovascular death and secondary outcome of 
non-cardiovascular death at one year across diagnostic categories. 
Results: Implementation increased the diagnosis of type 1 myocardial infarction by 11% 
(510/4,471), type 2 myocardial infarction by 22% (205/916),  and acute and chronic myocardial 
injury by 36% (443/1,233) and 43% (389/898), respectively. Compared to those without 
myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial 
infarction (cause-specific hazard ratio [csHR] 5.64, 95% confidence interval [CI] 5.12 to 6.22), 
but was similar across diagnostic categories, whereas non-cardiovascular deaths were highest in 
those with acute myocardial injury (csHR 2.65, 95%CI 2.33 to 3.01). Despite modest increases 
in anti-platelet therapy and coronary revascularization after implementation in patients with type 
1 myocardial infarction, the primary outcome was unchanged (csHR 1.00, 95%CI 0.82 to 1.21). 
Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to 
changes in investigation, treatment or outcomes. 
Conclusions: Implementation of high-sensitivity cardiac troponin and the recommendations of 
the Universal Definition of Myocardial Infarction identified patients at high-risk of 
cardiovascular and non-cardiovascular events, but was not associated with consistent increases in 
treatment or improved outcomes. Trials of secondary prevention are urgently required to 
determine whether this risk is modifiable in patients without type 1 myocardial infarction.   
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT0185212
Key Words: Myocardial injury; myocardial infarction; universal definition; troponin 
Non-standard Abbreviations and Acronyms: 
ACE: Angiotensin-Converting Enzyme 
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cTn: contemporary cardiac Troponin  
csHR: cause-specific Hazard Ratio 
High-STEACS: High-Sensitivity Troponin in the Evaluation of patients with suspected Acute 
Coronary Syndrome 
HR: Hazard Rratio 
hs-cTn: high-sensitivity cardiac Troponin 
hs-cTnI: high-sensitivity cardiac Troponin I 
IQR: Inter-Quartile Range 
MI: Myocardial Infarction 
NHS: National Health Service 
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Clinical Perspective 
 
What is new? 
• No previous randomised controlled trials have evaluated the effect of implementing a 
high-sensitivity cardiac troponin assay and the recommendations of the Universal 
Definition of Myocardial Infarction on the investigation, treatment and outcomes of 
patients stratified according to the proposed diagnostic classification. 
• We demonstrate that implementation of high-sensitivity cardiac troponin testing leads to 
a disproportionate increase in type 2 myocardial infarction and myocardial injury. 
• We found all patients with myocardial injury and infarction are at increased future 
cardiovascular risk, irrespective of aetiology, despite an excess in non-cardiovascular 
death in patients with type 2 myocardial infarction and myocardial injury. 
 
What are the clinical implications? 
• Clinicians should consider investigations to define coronary or structural heart disease in 
patients with type 2 myocardial infarction and myocardial injury 
• The risk of future cardiovascular events should be evaluated on an individual patient 
basis using all available clinical information 
• Until randomised controlled trials are available, secondary prevention therapies should be 
considered on a pragmatic basis with the aim of reducing future cardiovascular risk 
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Introduction 
The Universal Definition of Myocardial Infarction has evolved to accommodate improvements 
in the sensitivity of cardiac troponin assays.1-3 This international guideline recommends the use 
of high-sensitivity cardiac troponin (hs-cTn) assays and the 99th centile upper reference limit as 
the diagnostic threshold for myocardial infarction.4-7 It also recognises that myocardial injury 
occurs in many conditions other than acute coronary syndromes,8-11 and therefore proposes 
additional criteria for the classification of patients with myocardial injury and infarction based on 
aetiology.2,12  
 Despite nearly half of all elevations in cardiac troponin occurring in patients with type 2 
myocardial infarction or myocardial injury,13 this classification and its consequences for patients 
are not well understood in practice. We recently reported the primary outcome from a 
multicentre randomised controlled trial evaluating the impact of implementing a hs-cTnI assay 
on clinical outcomes in consecutive patients with suspected acute coronary syndrome.14 The 
introduction of hs-cTn reclassified one in six patients with myocardial necrosis who were not 
identified by the previous generation troponin assay, but this was not associated with an 
improvement in outcomes. In this pre-specified secondary analysis of the trial, we report whether 
implementing hs-cTn testing and the recommendations of the Universal Definition of 
Myocardial Infarction led to changes in investigation, treatment and outcomes in 
patients stratified according to the proposed diagnostic classification. 
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Methods  
Transparency and openness promotion 
The trial makes use of multiple routine electronic health care data sources that are linked, 
deidentified and held in our national safe haven, which is accessible by approved individuals 
who have undertaken the necessary governance training. Summary data and the analysis code 
can be made available upon request from the corresponding author.  
Study Population and Trial Design 
High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary 
Syndrome (High-STEACS) is a stepped-wedge cluster randomised controlled trial to evaluate 
implementation of a hs-cTnI assay and the recommendations of the Universal Definition of 
Myocardial Infarction in consecutive patients with suspected acute coronary syndrome, across 
ten secondary and tertiary care hospitals in Scotland. All patients attending the Emergency 
Department were screened for suspected acute coronary syndrome by the attending clinician at 
the time troponin was requested, using an electronic form integrated into the clinical care 
pathway. Patients were eligible for inclusion if they presented with suspected acute coronary 
syndrome and had paired cardiac troponin measurements from the standard care and trial assay. 
Patients were excluded if they had been admitted previously during the trial period or were not 
resident in Scotland.  
Randomisation  
All sites reported cardiac troponin using a contemporary troponin assay and existing diagnostic 
threshold in a validation phase of at least 6 months, before being randomly allocated to early or 
late implementation of a high-sensitivity assay with sex-specific 99th centile thresholds as 
recommended by the Universal Definition (Supplementary Appendix A).  
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Intervention 
Cardiac troponin testing was performed at presentation and was repeated 6 or 12 h after the onset 
of symptoms at the discretion of the attending physician and in accordance with national 
guidelines.15 In the validation phase, a contemporary cardiac troponin I (cTnI) assay (Abbott 
Laboratories, Abbott Park, IL, USA) was used to guide clinical decisions. The inter-assay 
coefficient of variation was determined at each site and was less than 10% at 40 ng/L (seven 
sites) and 50 ng/L (three sites). Only cTnI concentrations above these diagnostic thresholds were 
reported. During the implementation phase, a hs-cTnI assay (ARCHITECTSTAT high-sensitive 
troponin I assay; Abbott Laboratories, Abbott Park, IL, USA) was used to guide clinical 
decisions. This assay has an inter-assay coefficient of variation of less than 10% at 4.7 ng/L, and 
a 99th centile upper reference limit of 34 ng/L in men and 16 ng/L in women.4  
To support implementation, we provided written educational material and presentations 
at each site, and updated the electronic patient record to highlight the change in assay and 
diagnostic thresholds. Educational material on the new assay, decision thresholds, and on the 
classification of myocardial injury and infarction were presented at each Emergency Department 
handover (twice daily). A detailed summary of the trial procedures and intervention is available 
in Supplementary Appendix A. 
Adjudication of Myocardial Injury and Infarction 
All diagnoses in patients with hs-cTnI concentrations above the 99th centile were adjudicated and 
classified according to the Third Universal Definition of Myocardial Infarction.1 In this pre-
specified secondary analysis, this classification was updated to the Fourth Universal Definition 
of Myocardial Infarction.2 Two physicians independently reviewed all clinical information, 
blinded to study phase, with discordant diagnoses resolved by a third reviewer.  Type 1 
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myocardial infarction was defined as myocardial necrosis (any hs-cTnI concentration above the 
sex-specific 99th centile with a rise and/or fall in hs-cTnI concentration where serial testing was 
performed) in the context of a presentation with suspected acute coronary syndrome with 
symptoms or signs of myocardial ischemia on the electrocardiogram. Patients with myocardial 
necrosis, symptoms or signs of myocardial ischemia, and evidence of increased myocardial 
oxygen demand or decreased supply secondary to an alternative condition without evidence of 
acute atherothrombosis were defined as type 2 myocardial infarction. Patients with hs-cTnI 
concentrations above the 99th centile without symptoms or signs of myocardial ischemia were 
classified as having myocardial injury. The final clinical diagnosis was also adjudicated 
according to prespecified criteria. All non-ischemic myocardial injury was classified as acute, 
unless a change of ≤20% was observed on serial testing,2 or the final adjudicated diagnosis was 
chronic heart failure or chronic renal failure, where the classification was chronic myocardial 
injury. A detailed summary of the adjudication procedures is provided in Supplementary 
Appendix B. 
Trial Outcomes  
We used regional and national registries to ensure complete follow-up for the trial population.16 
The primary outcome was myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 
year. Primary outcome events were adjudicated by a panel who were blinded to the index 
presentation and study phase (Supplementary Appendix A). Secondary outcomes included all-
cause death, cardiovascular death, cardiac death, non-cardiovascular death, duration of stay, 
myocardial infarction (type 1 or type 4b), unplanned coronary revascularisation, hospitalisation 
for heart failure, ischemic stroke, major haemorrhage and unplanned hospitalisation.  
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Ethical Approval 
The study was approved by the Scotland A Research Ethics Committee, the Public Benefit and 
Privacy Panel for Health and Social Care, and by each National Health Service (NHS) Health 
Board. All data were collected prospectively from the electronic patient record, deidentified and 
linked within secure NHS Safe Havens.  
Patient and public involvement 
Both patients and lay representatives were members of the trial steering committee for the High-
STEACS clinical trial and all related studies (NCT:01852123) and were involved in the design, 
conduct and approval of this study.  
Statistical Analysis 
Baseline characteristics were summarised for the study population and in groups according to the 
universal definition classification. We assessed agreement between adjudicators across 
diagnostic categories using Cohen’s Kappa. Group-wise comparisons were performed using Chi-
square, Kruskal Wallis or one-way analysis of variance tests as appropriate. In post-hoc analysis, 
we compared management by classification, with type 1 myocardial infarction as the reference 
group, including a Bonferroni correction for multiple testing. Based on prior observations of an 
excess in non-cardiovascular death in patients with type 2 myocardial infarction and myocardial 
injury,11 we applied competing risks methodology in all analyses.17 The risk of the primary 
outcome and competing risk of non-cardiovascular death was estimated using a cumulative 
incidence function.18 Outcome rates were compared between groups using cause-specific hazard 
ratios obtained from a Cox regression model, with patients without myocardial injury as the 
referent group. The model was adjusted for age, sex, a history of ischemic heart disease or 
diabetes mellitus, renal function (creatinine concentration), time of presentation from the start 
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date of the trial, season, site of recruitment (as a random effect) and phase of the trial. Where 
data were missing for creatinine concentration (1.9%, 948/48,282) this was assumed to be at 
random, and multiple imputation was applied using chained equations with five imputations of 
the data set. We compared the rates of the primary outcome before and after implementation of 
the high-sensitivity assay by group using an identical Cox proportional hazards model, including 
additional terms for the log transformed peak troponin concentration and interaction terms for 
phase of the trial and diagnostic group. All analyses were pre-specified (Supplementary 
Appendix C) and performed in R (Version 3.5.1) using the survival and cmprsk packages.  
 
Results 
Trial Sites and Population 
We enrolled 48,282 patients (61±17 years, 47% women) with suspected acute coronary 
syndrome across ten sites with 39% (18,978/48,282) and 61% (29,304/48,282) enrolled during 
the validation and implementation phase, respectively.  
Classification by the Universal Definition of Myocardial Infarction 
During the index presentation, 21% (10,360/48,282) of patients had hs-cTnI concentrations 
above the 99th centile (Figure 1). It was possible to adjudicate the diagnosis in 88% 
(9,115/10,360) of patients (Table S1), and there was substantial agreement between adjudicators 
(=0.75). The adjudicated diagnosis was type 1 myocardial infarction in 55% (4,981/9,115), 
type 2 myocardial infarction in 12% (1,121/9,115), and acute or chronic myocardial injury in 
18% (1,676/9,115) and 14% (1,287/9,115), respectively (Table 1). Diagnostic agreement was 
substantial in patients with type 1 myocardial infarction (K=0.78) and myocardial injury 
(K=0.65), but was lower in those with type 2 myocardial infarction (K=0.49). Compared to the 
D
ow
nloaded from
 http://ahajournals.org by on October 14, 2019
10.1161/CIRCULATIONAHA.119.042960 
10 
Third Universal Definition,14 adoption of the recommendations from the Fourth Universal 
Definition reclassified 15% (1,320/9,115) of patients, with the majority of those reclassified 
having chronic myocardial injury (Figure S1). The use of objective criteria for myocardial 
oxygen supply or demand imbalance as proposed in the Fourth Definition led to an improvement 
in diagnostic agreement in those with type 2 myocardial infarction (K=0.62). 
Compared to those with type 1 myocardial infarction, patients with type 2 myocardial 
infarction were older (74±14 versus  68±14 years), were more likely to be women (55% versus 
40%), and more likely to have a history of cardiovascular disease. Patients with acute or chronic 
myocardial injury were of similar age and sex to those with type 2 myocardial infarction. Peak 
troponin concentrations were higher in patients with type 1 myocardial infarction (855 ng/L, 
interquartile range (IQR) 104 to 6,775 ng/L) compared to type 2 myocardial infarction (125 
ng/L, 48 to 604 ng/L) and either acute or chronic myocardial injury (74 ng/L, IQR 37 to 307 
ng/L, and 55 ng/L, IQR 34 to 145 ng/L, respectively; Table 1).  
Management by classification 
The majority of patients with type 1 myocardial infarction were started on anti-platelet or anti-
coagulant therapy in the emergency department (55%), and had coronary angiography (59%)  or 
percutaneous coronary intervention (41%) during the index presentation (Table 2). Patients were 
likely to receive additional treatments including single (67%) or dual (60%) anti-platelet, 
angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (32%), 
beta-blocker (38%) or statin (35%) therapies. Fewer patients with type 2 myocardial infarction 
received anti-platelet or anti-coagulant therapy at presentation (26%), or underwent coronary 
angiography (10%) and percutaneous coronary intervention (2%, P<0.001 for all). On discharge, 
patients with type 2 myocardial infarction were less likely to receive new treatment with single 
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(19%) or dual (10%) anti-platelet, ACE inhibitor or ARB (9%), beta-blocker (20%) or statin 
(6%) therapies (P<0.001 for all). Patients with acute or chronic myocardial injury received fewer 
therapies than patients with type 1 or type 2 myocardial infarction (P<0.001 for all).  
Outcomes by classification 
The primary outcome of subsequent myocardial infarction or cardiovascular death occurred in 
17% (863/4,981) of patients with type 1 myocardial infarction, and in 14% (162/1,121) with type 
2 myocardial infarction, 16% (273/1,676) with acute myocardial injury, and 16% (207/1,287) 
with chronic myocardial injury, respectively (Table S2). When compared to those without 
myocardial injury, the risk and rate of the primary outcome was highest in patients with type 1 
myocardial infarction (Figure 2, cause-specific Hazard Ratio [csHR] 5.64, 95%CI 5.12 to 6.22), 
but increases were also observed in patients with type 2 myocardial infarction (csHR 3.50, 
95%CI 2.94 to 4.15), acute myocardial injury (csHR 4.38, 95%CI 3.80 to 5.05) and chronic 
myocardial injury (csHR 3.88, 95%CI 3.31 to 4.55, Figure 3, Table S3). The rate of future type 
1 or 4b myocardial infarction at one year was highest in those with an index type 1 myocardial 
infarction (9%, 466/4,981), and lower in those with type 2 myocardial infarction (5%, 
51/1,1121), acute (3%, 56/1,676) or chronic myocardial injury  (4%, 57/1,287).  
Death from any cause occurred in 9% (4,367/48,282) of patients, with those with acute 
myocardial injury at highest risk (Figure S2). The proportion of deaths from cardiovascular and 
non-cardiovascular causes differed across diagnostic categories (Figure 4). The risk and rate of 
death from a non-cardiovascular cause was highest in patients with acute myocardial injury 
(Figure 2, csHR 2.65, 95%CI 2.33 to 3.01), type 2 myocardial infarction (csHR 1.72, 95%CI 
1.44 to 2.06) and chronic myocardial injury (csHR 2.06, 95%CI 1.77 to 2.40), and was lowest in 
patients with type 1 myocardial infarction (csHR 0.83, 95%CI 0.72 to 0.96).  
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Implementation of the high-sensitivity assay 
In the implementation phase, the use of high-sensitivity troponin increased the diagnosis of type 
1 myocardial infarction by 11% (510/4,471), type 2 myocardial infarction by 22% (205/916), 
acute myocardial injury by 36% (443/1,233) and chronic myocardial injury by 43% (389/898). 
Despite increases in the use of anti-platelet and anticoagulant therapies (43% versus 61%) and 
coronary revascularisation (35% versus 44%), there was no reduction in the primary outcome in 
patients with type 1 myocardial infarction (csHR 1.00, 95%CI 0.82 to 1.21, Table S4 and S5, 
Figure S3 and S4). Implementation was not associated with additional treatment or 
improvement in outcomes for patients with type 2 myocardial infarction or myocardial injury 
(Table S4 and S5, Figure S3 and S4).  
 
Discussion 
In a randomised controlled trial, we evaluated the effect of implementing a high-sensitivity 
cardiac troponin I assay and the recommendations of the Universal Definition of Myocardial 
Infarction on clinical outcomes in consecutive patients with suspected acute coronary syndrome. 
Whilst the majority of patients had a diagnosis of type 1 myocardial infarction, the introduction 
of high-sensitivity troponin testing led to a disproportionate increase in the diagnosis of type 2 
myocardial infarction and myocardial injury. All patients with myocardial injury or infarction 
were at increased risk of future myocardial infarction or cardiovascular death, with those with 
type 1 myocardial infarction at highest risk. Despite modest increases in coronary 
revascularisation and preventative therapies in patients with type 1 myocardial infarction, there 
was no reduction in future cardiovascular events. In patients with type 2 myocardial infarction or 
myocardial injury, cardiovascular event rates and future risk was similar to patients with type 1 
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myocardial infarction, despite a marked increase in non-cardiovascular death. Here, we observed 
no change in cardiovascular investigations or treatments, and outcomes were similarly 
unchanged.  
The observed excess in mortality in patients with type 2 myocardial infarction or 
myocardial injury is consistent with prior observational studies.8,11,13,19-28 Patients with acute 
myocardial injury were at highest risk of non-cardiovascular death, with more than a third 
occurring within 30 days due to pneumonia, an infective exacerbation of chronic obstructive 
pulmonary disease or sepsis. In a model attempting to account for this competing risk of non-
cardiovascular death, patients with type 2 myocardial infarction or myocardial injury had lower 
rates of cardiovascular events than those with type 1 myocardial infarction. Despite this, one in 
six had a myocardial infarction or died from a cardiovascular cause at one year; an event rate 
over three-fold higher than observed in those without evidence of myocardial injury.  
Whilst high-sensitivity cardiac troponin clearly provides important prognostic 
information, implementation of testing into practice did not improve outcomes. This may be 
because in patients with type 2 myocardial infarction or myocardial injury, there is little 
consensus on how to investigate or treat either group. Even in those with type 1 myocardial 
infarction, where we have clear guidelines for investigation and treatment, we observed only 
modest increases in coronary angiography, anti-platelet or other preventative therapies. This may 
reflect clinician uncertainty in whether small increases in cardiac troponin are important, and if 
the benefits of invasive management outweigh the risks in this group. Indeed, our evidence base 
for the management of myocardial infarction largely predates the introduction of the Universal 
Definition, when the diagnostic threshold for myocardial infarction was almost ten-fold higher 
than the threshold implemented in this trial.  
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The lack of a specific cardiac biomarker to distinguish type 1 myocardial infarction, and 
the increasing frequency of type 2 myocardial infarction and myocardial injury poses challenges 
to clinicians in practice on a daily basis. As observed in this trial, type 2 myocardial infarction 
and myocardial injury are responsible for almost half of all elevations in cardiac troponin 
concentration, and have been shown to be more frequent than type 1 myocardial infarction in 
hospitalised patients over the age of 75.13 Less than half of these patients are referred to 
cardiology, with the majority managed by general physicians,13 and a lack of evidence has led to 
inconsistency in investigation and treatment.  
The classification of type 2 myocardial infarction and myocardial injury is based on 
expert consensus, and to date no prospective clinical trials have evaluated the utility of this 
classification.29 These conditions arise due to a wide range of pathologies including coronary or 
structural heart disease, arrhythmias, myocarditis and many non-cardiac conditions.8 The latest 
guidance, requiring evidence of myocardial ischemia and oxygen supply-demand imbalance, has 
reduced the frequency of type 2 myocardial infarction. Our observations add to previous studies 
suggesting that any myocardial injury is prognostically important,11,30,31 irrespective of whether 
myocardial ischemia was present, but strategies to guide further investigation and treatment in 
patients without type 1 myocardial infarction require prospective evaluation.  
Whilst implementation of high-sensitivity troponin and the recommendations of the 
Universal Definition did not improve outcomes here, the proposed framework of classification 
could be helpful as it encourages clinicians to consider the underlying mechanism of myocardial 
injury, and to not dismiss troponin elevation as mere bystander injury of no consequence.  
The Fourth Universal Definition states patients with type 2 myocardial infarction should 
not have evidence of acute atherothrombosis, which may encourage clinicians to undertake 
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additional coronary investigations. If recognition of type 2 myocardial infarction or acute 
myocardial injury during another illness leads to the identification and treatment of previously 
unrecognised coronary or structural heart disease, it is plausible that cardiovascular outcomes 
could improve.16 Indeed there is increasing evidence that the presence of obstructive coronary 
disease is the strongest predictor of future adverse cardiovascular outcomes.11,30,31 Identification 
of those with chronic myocardial injury may also be useful, as this may indicate the presence of 
unrecognised stable cardiovascular disease. A prospective trial of coronary and cardiac imaging 
in type 2 myocardial infarction is in progress (DEMAND-MI, ClinicalTrials.gov 
NCT:03338504), and a randomised controlled trial of coronary investigation and targeted 
preventative therapy is planned.32 These studies are an appropriate first step in the understanding 
of this heterogeneous group of patients and will help to refine the classification and provide 
clearer guidance for clinicians in practice. Randomised controlled trials of secondary prevention 
therapy are urgently required, but until such data are available to inform clinical guidelines, 
clinicians should carefully assess cardiovascular risk on an individual patient basis to guide 
investigation and secondary prevention.  
There are several strengths and limitations of our study. This was a pre-specified 
secondary analysis of a randomised controlled trial, enrolling consecutive patients with suspected 
acute coronary syndrome across ten hospitals irrespective of age, sex, time of presentation and 
severity of illness. As such, we believe our results are generalisable and reflective of real-world 
clinical practice. Using all available clinical information, we reviewed and classified all patients 
according to the latest recommendations from the Universal Definition of Myocardial Infarction 
to ensure our findings are relevant to current practice. Where there was consensus amongst the 
adjudication panel that there was insufficient clinical information to make a definitive diagnosis, 
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due to missing admission or discharge letters, we did not attempt to adjudicate the diagnosis 
(1,245/10,360, 12%). We had access to all other information including past medical history, 
clinical investigations, management and outcomes, and provide data for all primary and 
secondary outcomes in this group within the data supplement (Table S1 and S2). Our trial 
population was restricted to patients who had cardiac troponin measured for suspected acute 
coronary syndrome, and we acknowledge that the prevalence of type 2 myocardial infarction and 
myocardial injury may differ in consecutive patients where cardiac troponin was measured for 
any reason.(33,34) Whilst we implemented the recommendations of the Third Universal Definition 
in our trial, as the Fourth Universal Definition provides no additional guidance on the 
investigation or treatment of patients with type 2 myocardial infarction or myocardial injury, we 
think it is unlikely that outcomes would differ had this guideline been in place at the start of the 
trial. Whilst there was substantial overall agreement between adjudicators for the classification 
of myocardial injury and infarction, we recognize that agreement was only moderate for the 
classification of type 2 myocardial infarction or myocardial injury. In addition, we acknowledge 
that investigations and treatments were undertaken at the discretion of the treating clinician there 
is a risk of diagnostic misclassification. A formal comparison of the adjudicated diagnosis and 
ICD-10 coded clinical diagnosis is planned. Serial cardiac troponin measurements were only 
undertaken in 77% (6,983/9,115) of patients, which has particular relevance to the distinction 
between acute and chronic myocardial injury. Consequently, we considered both diagnoses as a 
single entity when comparing outcomes by study phase to avoid selection bias.   
In conclusion, implementation of the recommendations of the Universal Definition of 
Myocardial Infarction identified patients at high risk of cardiovascular and non-cardiovascular 
events, but was not associated with consistent increases in treatment or improved outcomes. 
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Effective strategies for the investigation and treatment of patients with type 2 myocardial 
infarction and myocardial injury are required if we are to improve outcomes.  
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Table 1. Characteristics of the Trial Participants Classified by the Fourth Universal Definition of Myocardial Infarction 
 
 
All patients No myocardial 
injury 
Type 1 
myocardial 
infarction  
Type 2 
myocardial 
infarction 
Acute 
myocardial 
injury 
Chronic 
myocardial 
injury 
No. of participants 48,282 37,922 4,981 1,121 1,676 1,287 
Age (years), mean (SD) 61 (17) 58 (17) 68 (14) 74 (14) 75 (15) 74 (15) 
Men, n (%) 25,720 (53) 20,351 (54) 2,995 (60) 501 (45) 664 (40) 536 (42) 
Phase       
Validation 18,978 (39) 14,862 (39) 1,794 (36) 405 (36) 683 (41) 498 (39) 
Presenting symptom*       
  Chest pain, n (%) 34,540 (81) 28,091 (84) 4,061 (89) 749 (73) 569 (38) 559 (49) 
  Dyspnoea, n (%) 2,175 (5) 1,107 (3) 171 (4) 116 (11) 372 (25) 235 (21) 
  Palpitation, n (%) 1,269 (3) 991 (3) 17 (<1) 67 (6) 97 (6) 42 (4) 
  Syncope, n (%) 2,495 (6) 1,809 (5) 102 (2) 38 (4) 240 (16) 179 (16) 
  Other, n (%) 2,188 (5) 1,458 (4) 221 (5) 61 (6) 217 (15) 116 (10) 
Past medical history       
  Myocardial infarction, n (%) 4,214 (9) 2,835 (7) 667 (13) 163 (15) 161 (10) 205 (16) 
  Ischemic heart disease, n (%) 11,912 (25) 8,455 (22) 1,519 (30) 454 (40) 509 (30) 492 (38) 
  Cerebrovascular disease, n (%) 2,949 (6) 1,915 (5) 368 (7) 135 (12) 192 (11) 167 (13) 
  Diabetes mellitus, n (%) 3,518 (7) 2,040 (5) 802 (16) 147 (13) 208 (12) 164 (13) 
  Heart failure hospitalisation, n (%) 4,322 (9) 2,159 (6) 792 (16) 292 (26) 410 (24) 363 (28) 
Previous revascularisation       
  PCI, n (%) 3,682 (8) 2,744 (7) 487 (10) 97 (9) 94 (6) 128 (10) 
  CABG, n (%) 782 (2) 534 (1) 105 (2) 32 (3) 45 (3) 34 ( 3) 
Medications at presentation       
  Aspirin, n (%) 13,163 (27) 9,462 (25) 1,694 (34) 471 (42) 608 (36) 452 (35) 
  Dual anti-platelet therapy, n (%)† 1,605 (3) 1,103 (3) 233 (5) 64 (6) 71 (4) 68 (5) 
  Statin, n (%) 19,366 (40) 14,106 (37) 2,377 (48) 632 (56) 852 (51) 686 (53) 
  ACE inhibitor or ARB, n (%) 15,618 (32) 11,285 (30) 1,995 (40) 514 (46) 692 (41) 579 (45) 
  Beta-blocker, n (%) 13,173 (27) 9,566 (25) 1,598 (32) 489 (44) 564 (34) 460 (36) 
  Oral anti-coagulant, n (%)‡ 3,253 (7) 2,158 (6) 292 ( 6) 170 (15) 225 (13) 198 (15) 
Electrocardiogram§       
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  Normal  - - 1,578 (32) 201 (18) 400 (24) 363 (28) 
  Myocardial ischemia - - 1,872 (38) 383 (34) 112 (7) 75 (6) 
  ST-segment elevation - - 870 (17) 36 (3) 38 (2) 40 (3) 
  ST-segment depression - - 865 (17) 278 (25) 87 (5) 56  4) 
  T-wave inversion - - 780 (16) 166 (15) 128 (8) 148 (11) 
Physiological parameters§       
  Heart rate, beats per minute - - 79 (20) 105 (35) 94 (29) 85 (24) 
  Systolic blood pressure, mmHg - - 142 (28) 132 (30) 136 (31) 137 (29) 
Hematology and clinical chemistry       
  Haemoglobin, g/L  136 (22) 137 (20) 136 (22) 126 (29) 128 (25) 127 (24) 
  eGFR, ml/min 54 (13) 56 (10) 51 (14) 46 (15) 45 (16) 45 (17) 
  Peak hs-cTnI, ng/L 4 [2, 16] 3 [1, 6] 855 [104, 6775] 125 [48, 604] 74 [37, 307] 55 [34, 145] 
Presented as mean (SD), median (inter-quartile range), or number (%). There were significant differences (P<0.001) between groups for all co-
variates. P values obtained from group-wise comparisons using Chi-square, Kruskal Wallis or one way analysis of variance tests as 
appropriate. Cell counts <5 are redacted in line with regulatory approvals.  
*Presenting symptom was missing in 5,615 (12%) patients.  
†Two medications from aspirin, clopidogrel, prasugrel or ticagrelor. ‡Includes warfarin or novel oral anti-coagulants.  
§ Electrocardiographic findings and physiological parameters only reported for those with elevation in cardiac troponin concentrations.   
Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blockers; eGFR = estimated glomerular filtration rate; 
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.  
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Table 2. Management During Index Hospital Admission Stratified by the Fourth Universal Definition of Myocardial 
Infarction 
 
 All patients No myocardial 
injury 
Type 1 
myocardial 
infarction 
Type 2 
myocardial 
infarction 
Acute 
myocardial  
injury 
Chronic 
myocardial  
injury 
No. of participants 48,282 37,922 4,981 1,121 1,676 1,287 
Duration of stay, hrs 9 [3, 39] 5 [3, 22] 75 [41, 126] 96 [37, 201]* 114 [23, 284]* 116 [38, 290]* 
ACS treatment in ED 3,458 (34) <5 (<1) 2,717 (55) 294 (26)* 199 (12)* 209 (16)* 
New anti-platelet agent 5,865 (12) 1,771 (5) 3,354 (67) 209 (19)* 165 (10)* 185 (14)* 
New dual anti-platelet 
therapy‡ 
3,967 (8) 584 (2) 2,969 (60) 116 (10)* 76 (5)* 94 (7)* 
Coronary angiography† 3,786 (8) 515 (1) 2,928 (59) 115 (10)* 63 (4)* 72 (6)* 
PCI 2,370 (5) 267 (1) 2,021 (41) 17 (2)* <5 (<1)* 6 (<1)* 
       
New ACE inhibitor or 
ARB 
2,711 (6) 766 (2) 1,577 (32) 104 (9)* 92 (5)* 96 (7)* 
New beta-blocker 4,416 (9) 1,857 (5) 1,878 (38) 219 (20)* 175 (10)* 153 (12)* 
New statin therapy 3,061 (6) 1,027 (3) 1,764 (35) 68 (6)* 58 (3)* 80 (6)* 
New oral anticoagulant 1,477 (3) 834 (2) 129 (3) 209 (19)* 153 (9)* 78 (6)* 
Values are number (%) or median (inter-quartile range). There were significant differences (P<0.001) between groups for all 
co-variates. P values obtained from group-wise comparisons using Chi-square or Kruskal Wallis as appropriate.  
Abbreviations: ACE = angiotensin converting enzyme; ACS = acute coronary syndrome; ARB = angiotensin receptor blockers; 
CABG = coronary artery bypass grafting; ED = Emergency Department; PCI = percutaneous coronary intervention. Cell 
counts <5 are redacted in line with regulatory approvals. 
* P value <0.001 in post-hoc analysis with type 1 myocardial infarction as the reference group, with Bonferroni correction for 
multiple testing. 
† Angiography and revascularisation within 30 days of presentation  
‡ Two medications from aspirin, clopidogrel, prasugrel or ticagrelor  
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Figure Legends 
 
Figure 1. Consort diagram with identification of the study population by classification, and 
proportion identified by the contemporary troponin assay (cTnI) or reclassified by the high-
sensitivity assay (hs-cTnI). Serial cardiac troponin concentrations were available in 77% 
(6,983/9,115) of patients with myocardial injury. 
 
Figure 2. Cumulative incidence curves for the primary outcome of type 1 or 4b myocardial 
infarction or cardiovascular death, and competing risk of non-cardiovascular death, stratified by 
type 1 myocardial infarction (red), type 2 myocardial infarction (gold), acute myocardial injury 
(dark blue), chronic myocardial injury (light blue) and no myocardial injury (green) with table of 
number at risk. Estimates obtained from a cumulative incidence function.  
 
Figure 3. Forest plot of the primary outcome (type 1 or 4b myocardial infarction or 
cardiovascular death) and non-cardiovascular death in the trial population stratified by index 
diagnosis; type 1 myocardial infarction (red), type 2 myocardial infarction (gold), acute 
myocardial injury (dark blue) and chronic myocardial injury (light blue), relative to those with 
no myocardial injury. Adjusted cause-specific hazard ratios (csHR) obtained from multivariable 
cox regression models including adjustment for age, sex, a history of ischemic heart disease or 
diabetes mellitus, renal function, time of presentation from the start date of the trial, season, 
phase of the trial and site of recruitment (as a random effect). In this model the competing event 
or time of censor are both considered as independent outcomes. 
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Figure 4. Flow diagram (alluvial plot) illustrating the frequency of cause of death grouped by 
classification of myocardial infarction and cardiovascular or non-cardiovascular causes.  Type 1 
myocardial infarction (red), type 2 myocardial infarction (gold), acute myocardial injury (dark 
blue) and chronic myocardial injury (light blue). All causes of death which occurred in five or 
more patients are included, with the width of band indicating the relative size of the population.  
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